Long-term efficiency of infliximab in patients with ankylosing spondylitis: Real life data confirm the potential for dose reduction

RMD Open

Volumn 2, Issue 2, 2016, Pages

  Baraliakos, X ^a   Heldmann, F ^b   Van Den Bosch, F ^c   Burmester, G ^d   Gaston, H ^e   Van Der Horst Bruinsma, I E ^f   Krause, A ^g   Schmidt, R ^h   Schneider, M ⁱ   Sieper, J ^d   Andermann, B ^j   Van Tubergen, A ^k   Witt, M ^l   Braun, J ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b Zeisigwaldkliniken Bethanien   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MARTIN LUTHER KRANKENHAUS   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j Private Internal Medicine Practice   (Germany)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988311235     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000272     Document Type: Article

References (13)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
3. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
4. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
5. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-15.
6. Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013;15:R67.
7. Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011;50:1690-9.
8. Boonen A, Mau W. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4 Suppl 55):S112-17.
9. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
10. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29:672-80.
11. Heldmann F, Baraliakos X, Kiltz U, et al. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): longterm extension over 7 years with focus on clinical efficacy and safety. Clin Exp Rheumatol 2016;34:184-90.
12. Ramiro S, van Tubergen A, Stolwijk C, et al. Reference intervals of spinal mobility measures in normal individuals: the mobility study. Ann Rheum Dis 2015;74:1218-24.
13. Heldmann F, Brandt J, Listing J, et al. European Ankylosing Spondylitis Infliximab Cohort (EASIC): outcome of patients who had discontinued infliximab after the end of ASSERT. Ann Rheum Dis 2009;68:625.